黄金城集团

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy

Nat Commun. 2021-05; 
Julia Koerner, Dennis Horvath, Valerie L Herrmann, Anna MacKerracher, Bruno Gander, Hideo Yagita, Jacques Rohayem, Marcus Groettrup
Products/Services Used Details Operation
Endotoxin Detection & Removal System Endotoxin levels of PLGA particles were detected by ToxinSensor™ Chromogenic LAL Endotoxin Assay according to the manufacturer’s instructions (#L00350, Genscript) Get A Quote

摘要

With emerging supremacy, cancer immunotherapy has evolved as a promising therapeutic modality compared to conventional antitumor therapies. Cancer immunotherapy composed of biodegradable poly(lactic-co-glycolic acid) (PLGA) particles containing antigens and toll-like receptor ligands induces vigorous antitumor immune responses in vivo. Here, we demonstrate the supreme adjuvant effect of the recently developed and pharmaceutically defined double-stranded (ds)RNA adjuvant Riboxxim especially when incorporated into PLGA particles. Encapsulation of Riboxxim together with antigens potently activates murine and human dendritic cells, and elevated tumor-specific CD8 T cell responses are superior to those obtained usin... More

关键词